Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide-Dexamethasone in Double ASCT for Newly Diagnosed Multiple Myeloma
NCT01341262Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Mar 2002
- Primary completion
- Oct 2007
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in multiple myeloma (MM), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Response rate to thal-dex induction at 120 days, Duration of response and 5 more. Started Mar 2002; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01341262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01341262.